Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...

Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion ...

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.